Cargando…
Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position
We have previously reported a series of anilinoquinazoline derivatives as potent and selective biochemical inhibitors of the RET kinase domain. However, these derivatives displayed diminished cellular potency. Herein we describe further optimisation of the series through modification of their physic...
Autores principales: | Jordan, Allan M., Begum, Habiba, Fairweather, Emma, Fritzl, Samantha, Goldberg, Kristin, Hopkins, Gemma V., Hamilton, Niall M., Lyons, Amanda J., March, H. Nikki, Newton, Rebecca, Small, Helen F., Vishwanath, Swamy, Waddell, Ian D., Waszkowycz, Bohdan, Watson, Amanda J., Ogilvie, Donald J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896930/ https://www.ncbi.nlm.nih.gov/pubmed/27086121 http://dx.doi.org/10.1016/j.bmcl.2016.03.100 |
Ejemplares similares
-
Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade
por: Watson, Amanda J., et al.
Publicado: (2016) -
The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity
por: Newton, Rebecca, et al.
Publicado: (2016) -
Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives
por: Li, Meng, et al.
Publicado: (2021) -
Docking study, synthesis and antimicrobial evaluation of some novel 4-anilinoquinazoline derivatives
por: Nasab, Rezvan Rezaee, et al.
Publicado: (2017) -
New Insights into 4-Anilinoquinazolines as Inhibitors of Cardiac Troponin I–Interacting Kinase (TNNi3K)
por: Asquith, Christopher R. M., et al.
Publicado: (2020)